After five and six months at room temperature, due to the desiccated nature of the agar in the competitor’s Petri plates, the lab changed comparison for control purposes to compare NanoLogix’s Petri plates to the competitor’s fresh, just-delivered nutrient plates. At both data points, NanoLogix’s Flatpack-preserved Petri plates provided the equivalent in detection results to fresh Petri plates.
The current testing process, a follow-up to the successful one-year cold storage tests for NanoLogix TSA that were completed in 2012, will continue for an additional six months.
NanoLogix to Exhibit at the American Society for Microbiology (ASM) BioDefense and Emerging Diseases Research Meeting in Washington DC, 25-27 February 2013.
The Company will exhibit its technology at booth 38 in the MARRIOTT WARDMAN PARK - HALLS B SOUTH & C, 2660 Woodley Rd. NW, Washington, DC 20008Additional information regarding the meeting can be found at the following link: http://www.asmbiodefense.org/ About NanoLogix, Inc. NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing. Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity For more information visit www.nanologix.com. This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.